@article{133b9e0bf02b44d8972c20877abf8ebe,
title = "National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - Full report",
abstract = "The leadership of the National Lipid Association convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. An Executive Summary of those recommendations was previously published. This document provides support for the recommendations outlined in the Executive Summary. The major conclusions include (1) an elevated level of cholesterol carried by circulating apolipoprotein B-containing lipoproteins (non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol [LDL-C], termed atherogenic cholesterol) is a root cause of atherosclerosis, the key underlying process contributing to most clinical atherosclerotic cardiovascular disease (ASCVD) events; (2) reducing elevated levels of atherogenic cholesterol will lower ASCVD risk in proportion to the extent that atherogenic cholesterol is reduced. This benefit is presumed to result from atherogenic cholesterol lowering through multiple modalities, including lifestyle and drug therapies; (3) the intensity of risk-reduction therapy should generally be adjusted to the patient's absolute risk for an ASCVD event; (4) atherosclerosis is a process that often begins early in life and progresses for decades before resulting a clinical ASCVD event. Therefore, both intermediate-term and long-term or lifetime risk should be considered when assessing the potential benefits and hazards of risk-reduction therapies; (5) for patients in whom lipid-lowering drug therapy is indicated, statin treatment is the primary modality for reducing ASCVD risk; (6) nonlipid ASCVD risk factors should also be managed appropriately, particularly high blood pressure, cigarette smoking, and diabetes mellitus; and (7) the measurement and monitoring of atherogenic cholesterol levels remain an important part of a comprehensive ASCVD prevention strategy.",
keywords = "Atherogenic cholesterol, Atherosclerotic cardiovascular disease, Clinical recommendations, Coronary heart disease, Dyslipidemia, Lipoproteins, Low-density lipoprotein cholesterol",
author = "Jacobson, {Terry A.} and Ito, {Matthew K.} and Maki, {Kevin C.} and Orringer, {Carl E.} and Bays, {Harold E.} and Jones, {Peter H.} and McKenney, {James M.} and Grundy, {Scott M.} and Gill, {Edward A.} and Wild, {Robert A.} and Wilson, {Don P.} and Brown, {W. Virgil}",
note = "Funding Information: T.A.J. discloses that in the past 12 months, he has received consulting fees from Merck and Co, Amarin, AstraZeneca, and Regeneron/Sanofi-Aventis. M.K.I. discloses that in the past 12 months, he received a research grant from Kowa Pharmaceuticals and consulting honorarium from Pfizer. K.C.M. discloses that he has received consulting fees and research grants from Abbvie , Matinas BioPharma , AstraZeneca , Pharmavite , Sancilio , and Trygg Pharmaceuticals . C.E.O. has nothing to disclose. In the past 12 months, H.E.B.'s research site has received research grants from Amarin , Amgen , Ardea , Arisaph , California Raisin Marketing Board , Catabasis , Cymabay , Eisai , Elcelyx , Eli Lilly , Esperion , Gilead , Hanmi , Hisun , Hoffman-La Roche , Home Access , Janssen , Johnson and Johnson , Merck , Necktar , Novartis , Novo Nordisk , Omthera , Orexigen , Pfizer , Pronova , Regeneron , Sanofi , Takeda , TIMI , VIVUS Inc , and Wpu Pharmaceuticals . In the past 12 months, H.E.B. has served as a consultant and/or speaker to Amarin, Amgen, Astra Zeneca, Bristol Meyers Squibb, Catabasis, Daiichi Sankyo, Eisai, Eli Lilly, Isis, Merck, Novartis, Novo Nordisk, Omthera, Regeneron, Sanofi, VIVUS Inc, Wpu Pharmaceuticals. P.H.J. discloses that he has received consulting honoraria from AstraZeneca, Atherotech Diagnostic Lab, Daiichi Sankyo, Inc, Merck and Co, and Sanofi/Regeneron. J.M.M. discloses that the company with which he is employed has received research grants from Sanofi , Regeneron , Amgen , Pfizer , Lily , and Esperion . S.M.G. discloses that he received an honorarium as a consultant to Sanofi. E.A.G. discloses that he has received consulting fees from Philips Medical Systems. R.A.W. discloses that he has received consulting honoraria from the National Institutes of Health, the Food and Drug Administration, and Atherotech, Inc. D.P.W. discloses that he has been a speaker for Osler Institute-Pediatric Review Course and participated on the advisory board of Aegerion Pharmaceuticals, and Synageva BioPharma Corp and further discloses that he has received research funding from Merck Sharpe & Dohme and Novo Nordisk Inc . W.V.B. is the editor of the Journal of Clinical Lipidology and further discloses that he has received consulting fees/honoraria from Amgen, Bristol-Myers Squibb, Genzyme, Pfizer, Inc, LipoScience, Inc, Merck and Co, Catabasis, GlaxoSmithKline, Medtelligence, and Vindico. Publisher Copyright: {\textcopyright} 2015 National Lipid Association.",
year = "2015",
month = mar,
day = "1",
doi = "10.1016/j.jacl.2015.02.003",
language = "English (US)",
volume = "9",
pages = "129--169",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "2",
}